You are here

Nubeqa

4 March 2020

The Australian Prescription Medicine Decision Summary provides a short overview of the TGA's evaluation process leading to the registration of a new prescription medicine on the Australian Register of Therapeutic Goods (ARTG).

More in-depth information about the evaluation will be available in the Australian Public Assessment Report (AusPAR) for a particular prescription medicine, which can be found on the AusPAR search page once published.

Australian prescription medicine decision summary

Summary of submission

Submission type
New chemical entity
Product name

Nubeqa

Active ingredients
Darolutamide
ATC codes
L02BB06
Decision
Approved
Date of decision
20 February 2020
Date of entry onto ARTG
26 February 2020
Original publication date
4 March 2020
ARTG numbers
316417, 317242
Black Triangle Scheme
Yes. This product will remain in the scheme for 5 years, starting on the date the product is first supplied in Australia
Sponsor
Bayer Australia Limited
Sponsor address
875 Pacific Highway, Pymble NSW 2073
Dose forms
Film coated tablet
Strength
300 mg
Other ingredients

Tablet core: Calcium hydrogen phosphate dehydrate, Croscarmellose sodium, Lactose monohydrate, Magnesium stearate, Povidone

Film coat: Hypromellose, Lactose monohydrate, Macrogol 3350, Titanium dioxide

Each film-coated tablet contains 176.9 mg of lactose (as lactose monohydrate).

Containers
Blister pack, bottle
Pack sizes

Blister pack: 112 tablets (7 x 16)

Bottle: 120 tablets

Routes of administration
Oral
Dosage

The recommended dose is 600 mg (two film-coated tablets of 300 mg) darolutamide taken twice daily, equivalent to a total daily dose of 1200 mg.

For further information refer to the Product Information.

Pregnancy category

D

Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.

What was approved?

Nubeqa (darolutamide) was approved for the following therapeutic use:

Nubeqa is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).

What is this medicine and how does it work?

What was the decision based on?

What steps were involved in the decision process?

What post-market commitments will the sponsor undertake?

  • Submit the final clinical study report for the ARAMIS study when available.
  • Nubeqa (darolutamide) is to be included in the Black Triangle Scheme. The Product Information (PI) and Consumer Medicines Information (CMI) for Nubeqa must include the black triangle symbol and mandatory accompanying text for five years, which starts from the date that the sponsor notifies the TGA of supply of the product.
  • The European Union-Risk Management Plan (EU-RMP) (version 0.1, date 31 January 2019; data lock point (DLP) 3 September 2018), with Australian Specific Annex (version 1.0, dated February 2019), included with submission PM-2019-01420-1-4, and any subsequent revisions, as agreed with the TGA will be implemented in Australia.

    An obligatory component of risk management plans is routine pharmacovigilance. Routine pharmacovigilance includes the submission of periodic safety update reports (PSURs). Unless agreed separately between the supplier who is the recipient of the approval and the TGA, the first report must be submitted to TGA no later than 15 calendar months after the date of this approval letter. The subsequent reports must be submitted no less frequently than annually from the date of the first submitted report until the period covered by such reports is not less than three years from the date of this approval letter. The annual submission may be made up of two PSURs each covering six months. If the sponsor wishes, the six monthly reports may be submitted separately as they become available.

    The reports are to at least meet the requirements for PSURs as described in the European Medicines Agency's Guideline on Good Pharmacovigilance Practices (GVP) Module VII-periodic safety update report (Rev 1), Part VII.B Structures and processes. Note that submission of a PSUR does not constitute an application to vary the registration. Each report must have been prepared within ninety calendar days of the data lock point for that report.

Further information

The latest Product Information (PI) and Consumer Medicines Information (CMI) can be found at: ARTG search.

Australian Public Assessment Reports (AusPARs) can be found at: AusPAR search.

The latest news and updates regarding therapeutic goods regulation can be found at: TGA news room.